My 10 reasons to BUY at these levels

I tried to summarise it all as good as possible. Feel free to add!

Outstanding Cohort A results at both 28 and 100 day mark
Overall Response of 100%, Complete Response of 50% and a survival rate of 87.5% at day 100 (sadly one patient passed away after developing pneumonia, which is common outcome after receiving a bone marrow transplant and was therefore not considered trial or treatment related), achieved in adults at a lower dose (in comparison, another asx listed company recently reported OR of 69%, CR of 29% and a survival rate of 78%)

Estimated news on final recruitment of Cohort B not too far away
With estimated completion date June 2018 according to clinicaltrials.gov and deducting the 100 day observation period, end of March/beginning of April likely period for announcement

FujiFilm and their licence option
Outstanding results in Cohort A, the urge to gain control of what looks to be the most promising GvHD product out there and to introduce it to the market (first product sale and royaltoes for us as early as end of 2019/beginning of 2020 possible), make FujiFilm "jump" early and NOT wait for another 90 days after getting the final report of our trial

Pre-clinical study results due in Quarter 1/ 2018
Both Acute Respirotary Distress Syndrom (ARDS) and Myocardnal Infarction (heart attack) due this quarter, each could potentially lead to additional clinial trials

Apceth
According to recent announcements including the AGM still "on the hook" for "other diseases", news could drop at any time

Celularity
MoU with a soon to be NASDAQ listed, and by big US boys backed up company. Big goals, yet also with what appears to be a limited supply of MSCs that may jeopardize achieving them.
Also remember "Twittergate"...
News could be around the corner, who knows

Fund rumours
Recently rumours have made the rounds of a certain Fund getting close to the 5% mark, at which they would be forced to announce becoming a substantial shareholder - for us a first and would add further to the validation of our technology as well as our business model.
Our recent trading patterns and discussions on here have a lot in common with RAP back in mid 2016, just before a sub holding announcement was made by a fund, which name has been mentioned on here very recently...

Cash estimted to last till 2019
Based on our current cash burn rate, the money in our bank should keep the light on until beginning/mid of 2019, but of course we will have directors converting options (strike price of 40c = "no brainer", even H C Wainwright picked up on that) and at least one licence option of US$3 mio. from FujiFilm likely to hit our account in the next few months as well

Left field
With 650 clinical trials in over 50 different disease targets all over the world, now that we have proof (half way) that our Cymerus MSCs are safe, the likelihood of left field interest for our cells has never been higher.
Roadshows like the one coming up in two weeks (Hong Kong and Shanghai) will help spread the word.

Biotech takeovers are HOT STUFF
TiGenix, VAL, Ablynx, Juno, Kite etc.

$5? $10? Cymerus is unique, a one-of-a-kind platform at the forefront of MSC therapy commercialisation and not a "one-hit-wonder"! Only discount reason of our "priceless-tag" I can think of is that we are still at the beginning...

Please note that this is my personal opinion and should not be considered as investment advice. Always do your own research!